RNTX Director Awarded 17,500 Options at $1.55 – Form 4 Filing

Rein Therapeutics (RNTX) filed a Form 4 on 23-Jul-2025 reporting the first equity award to director Reinhard J. Ambros.

Rhea-AI Filing Summary

Rein Therapeutics (RNTX) filed a Form 4 on 23-Jul-2025 reporting the first equity award to director Reinhard J. Ambros. The filing shows a single transaction: a stock-option grant for 17,500 common shares at an exercise price of $1.55 per share. The option vests 100% on the earlier of 23-Jul-2026 or the company’s 2026 annual meeting, contingent on continued service. No sales or open-market purchases were disclosed, and Table I lists no direct common-stock holdings. After the grant, Ambros’ beneficial ownership consists of 17,500 derivative securities held directly.

The transaction is routine director compensation and represents a modest potential dilution relative to RNTX’s total share count (not provided in the filing). Because it is an A code (award) rather than an open-market buy, it should not be interpreted as an active insider purchase. However, it does increase insider alignment by giving the director upside participation tied to share-price performance above $1.55.

Positive

• Director equity alignment: Stock-option grant ties board compensation to future share performance, potentially improving shareholder alignment.

Negative

• Incremental dilution: Adds 17,500 shares to fully diluted count, though impact is likely immaterial given typical small-cap share bases.

Insights

Corporate Governance Analyst

TL;DR: Routine option grant aligns new director with shareholders; minimal immediate impact.

This filing documents a standard equity incentive for a board member. The one-year cliff vesting and strike of $1.55 encourage Ambros to focus on share appreciation over the next 12 months. No cash compensation details are provided, so investors cannot assess total pay mix. Given the small absolute size—17,500 options—and absence of open-market activity, the event is governance-neutral with negligible dilution. It improves transparency but carries no direct valuation effect.

Small-Cap Equity Analyst

TL;DR: Option award is symbolic; unlikely to move RNTX’s share price.

The grant equates to only 17,500 potential shares, a fraction of typical small-cap floats. Because strike equals $1.55, upside exists only if RNTX trades above that level; otherwise the option is out-of-the-money. Absence of share purchases limits the market-signal value typically associated with insider buying. Overall, investors should view this as procedural, not a catalyst.

Insider Trade Summary

Grant/Award: 17,500 shares

Grant/Award 1 txn

Insider Ambros Reinhard J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	17,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 17,500 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.

FAQ

What did RNTX disclose in the 23-Jul-2025 Form 4?

The company reported a grant of 17,500 stock options at a $1.55 strike to director Reinhard J. Ambros.

How many RNTX shares does Reinhard J. Ambros now own?

Post-transaction, he beneficially owns 17,500 derivative securities and no reported direct common shares.

When do the granted options vest?

They vest in full on the earlier of 23-Jul-2026 or the 2026 annual meeting, subject to continued service.

Is the Form 4 transaction an insider purchase?

No. The code "A" indicates an award, not an open-market buy.

What is the exercise price of the options?

The options can be exercised at $1.55 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/23/2025 - 07:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Ambros Reinhard J.

(Last) (First) (Middle)

C/O REIN THERAPEUTICS, INC

12407 N. MOPAC EXPY. SUITE 250 #390

(Street)

AUSTIN TX 78758

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rein Therapeutics, Inc. [ RNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.55	07/23/2025		A		17,500		(1)	07/22/2035	Common Stock	17,500	$0	17,500	D

Explanation of Responses:

1. This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.

	/s/ Brian Windsor, attorney-in-fact for Reinhard J. Ambros	07/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.